Sugi Predict

Sugi Predict / Compounds / SCHEMBL2643601

SCHEMBL2643601

SCHEMBL2643601

COC(=O)c1ccc(CNc2ccc(C3=CCCCC3)cc2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 5/20 0.61
▸ CA2 P00918 5/20 0.61
▸ ALDH1A1 P00352 5/20 0.47
▸ MAPT P10636 3/20 0.47
▸ HPGD P15428 2/20 0.46
▸ LMNA P02545 2/20 0.46
▸ RAB9A P51151 3/20 0.45
▸ NPC1 O15118 2/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ MEN1 O00255 2/20 0.44
▸ KMT2A Q03164 2/20 0.44
▸ HKDC1 Q2TB90 1/20 0.44
▸ CA12 O43570 1/20 0.44
▸ CA7 P43166 1/20 0.44
▸ POLB P06746 1/20 0.44
▸ HIF1A Q16665 2/20 0.43
▸ LOXL2 Q9Y4K0 1/20 0.42
▸ AGTR1 P30556 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ ALOX5 P09917 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2653992 1.00 CA1 (0.61) CA1CA2ALDH1A1MAPTHPGD
SCHEMBL2944680 0.87 ALDH1A1 (0.48) CA1CA2ALDH1A1MAPTMEN1
SCHEMBL2950950 0.85 ALDH1A1 (0.47) CA1CA2ALDH1A1MAPTMEN1
SCHEMBL2949298 0.85 ALDH1A1 (0.47) CA1CA2ALDH1A1MAPTMEN1
SCHEMBL2949295 0.85 ALDH1A1 (0.47) CA1CA2ALDH1A1MAPTMEN1
SCHEMBL26090324 0.82 CA1 (0.48) CA1CA2ALDH1A1MAPTHPGD
SCHEMBL2649311 0.82 GCGR (0.47) CA1CA2ALDH1A1RAB9ANPC1
SCHEMBL13934091 0.82 CA1 (0.87) CA1CA2ALDH1A1MAPTHPGD
SCHEMBL12003042 0.80 HIF1A (0.58) CA1CA2ALDH1A1LMNAKMT2A
SCHEMBL5401793 0.78 ALDH1A1 (0.44) CA1CA2ALDH1A1MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists NOVO NORDISK A/S (DK) 2009-06-04 — — US disclosed
EP-1183229-B1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK AS (DK) 2005-10-26 — — EP disclosed
US-6953812-B2 Glucagon antagonists/inverse agonists NOVO NORDISK, INC. (DK) 2005-10-11 — — US disclosed
US-20050203108-A1 Glucagon antagonists/inverse agonists PFIZER INC 2005-09-15 — — US disclosed
US-6875760-B2 Glucagon antagonists/inverse agonists NOVO NORDISK A/S (DK) 2005-04-05 — — US disclosed
US-20050059611-A1 Glucagon antagonists/inverse agonists NOVO NORDISK A/S (DK) 2005-03-17 — — US disclosed
EP-1509509-A1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK A/S (DK) 2005-03-02 — — EP disclosed
US-6821960-B2 Glucagon antagonists/inverse agonists NOYO NORDISK PHARMACEUTICALS, INC. 2004-11-23 — — US disclosed
US-20040127560-A1 Glucagon antagonists/inverse agonists MADSEN PETER (DK) 2004-07-01 — — US disclosed
US-20040116483-A1 Glucagon antagonists/inverse agonists BEHRENS CARSTEN (DK) 2004-06-17 — — US disclosed
US-20030027849-A1 Glucagon antagonists/inverse agonists NOVO NORDISK A/S (DK) 2003-02-06 — — US disclosed
US-6503949-B1 Treating Type 2 diabetes, hyperglycemia, impaired glucose tolerance or obesity NORO NORDISK A/S (DK) 2003-01-07 — — US disclosed
US-20020187982-A1 Glucagon antagonists/inverse agonists NOVO NORDISK A/S (DK) 2002-12-12 — — US disclosed
US-20020143186-A1 Glucagon antagonists/inverse agonists PFIZER INC 2002-10-03 — — US disclosed
WO-2002040445-A1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK A/S (DK) 2002-05-23 — — WO disclosed
WO-2002040444-A1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK A/S (DK) 2002-05-23 — — WO disclosed
WO-2002040446-A1 GLUCAGON ANTAGONIST/INVERSE AGONIST NOVO NORDISK A/S (DK) 2002-05-23 — — WO disclosed
EP-1183229-A1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK A/S (DK) 2002-03-06 — — EP disclosed
WO-2002000612-A1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK A/S (DK) 2002-01-03 — — WO disclosed
WO-2000069810-A1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK A/S (DK) 2000-11-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040127560-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR CA1 4668/4885CA2 3329/4885ALDH1A1 4014/4885
US-20050059611-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR CA1 4635/4885CA2 3400/4885ALDH1A1 3770/4885
US-20050203108-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR CA1 4464/4885CA2 3233/4885ALDH1A1 3968/4885
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists GLP1R, GPR119, GCGR CA1 4464/4885CA2 3233/4885ALDH1A1 3968/4885
US-20030027849-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR CA1 4635/4885CA2 3400/4885ALDH1A1 3770/4885
US-20020187982-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR CA1 4635/4885CA2 3400/4885ALDH1A1 3770/4885
US-20020143186-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR CA1 4725/4885CA2 3711/4885ALDH1A1 4046/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.